



## **Gloucester Pharmaceuticals' Istodax® (romidepsin) Receives FDA Approval to Treat Cutaneous T-cell Lymphoma**

I am pleased to announce that my partner and co-founder, Jay Mohr, Managing Director of Locust Walk Partners, recently achieved a professional milestone. Jay was founding CEO of Gloucester Pharmaceuticals and was responsible for diligencing and in-licensing Istodax® from Fujisawa (now Astellas). During his tenure at Gloucester, Jay raised over \$30M in initial venture financing to secure the asset; negotiate the SPA; start pivotal trials and source key investigators; and recruit/hire the initial management team.

Gloucester's current team successfully executed a challenging pivotal trial in cutaneous T-cell lymphoma and recently announced that they received FDA approval in this indication. The news was featured in FierceBiotech on Friday, November 6, 2009 and earlier in the fall in BioCentury (September 7, 2009), when Istodax® received unanimous approval by the Oncology Drug Advisory Committee.

This important professional accomplishment is only one example of the critical thinking and focus on execution that sets Locust Walk Partners apart and adds value to our clients. We provide business development advisory that incorporates a solid operating perspective – including commercial, clinical and scientific rigor – all of which increases the probability of a successful deal outcome.

We would welcome the opportunity to explore how LWP may be able to support your BD and commercial initiatives. For further information, please contact:

### **Geoff Meyerson**

Managing Director

[geoff@locustwalkpartners.com](mailto:geoff@locustwalkpartners.com)

(610) 909-6105

### **Jay Mohr**

Managing Director

[jay@locustwalkpartners.com](mailto:jay@locustwalkpartners.com)

(617) 645-1575